Pathology of Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) represents a unique subtype characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. This track will delve into the intricate pathology of TNBC, exploring its clinical implications and therapeutic strategies. Attendees will gain insights into the aggressive nature of TNBC, its distinct molecular features, and the challenges associated with diagnosis and treatment. Discussion will focus on emerging biomarkers, novel targeted therapies, and immunotherapy approaches. By understanding the underlying pathology of TNBC, participants will be equipped to optimize patient management, improve prognostic evaluation, and contribute to the development of personalized therapeutic interventions.

 

 

    Related Conference of Pathology of Triple-Negative Breast Cancer

    March 10-11, 2025

    3rd World Congress on Oral Cancer

    Paris, France
    March 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    London, UK
    March 24-25, 2025

    10th World Conference on Breast and Cervical Cancer

    Paris, France
    April 07-08, 2025

    15th World Congress on Breast Cancer

    Vancouver, Canada
    June 16-17, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    July 14-15, 2025

    5th World Congress on Breast Cancer

    Berlin, Germany
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain

    Pathology of Triple-Negative Breast Cancer Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in